Weight-Loss drug wegovy could boost heart ablation success

NCT ID NCT07275697

Recruiting now Disease control Sponsor: Emma Svennberg Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 11, 2026 · Updated 2 times

Summary

This study tests whether taking semaglutide (Wegovy) for at least three months before a first-time atrial fibrillation ablation can improve heart rhythm outcomes. 200 overweight or obese adults scheduled for ablation will be randomly assigned to either standard care or semaglutide plus lifestyle advice. The main goal is to see if semaglutide reduces the chance of abnormal heart rhythms returning within a year after the procedure.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Semaglutide (Wegovy), a weight-loss drug
What this could lead to: If successful, this could show that using a weight-loss drug before heart ablation improves long-term heart rhythm control and reduces the need for repeat procedures.
What could go wrong: This is a Phase 4 trial with only 200 participants, so results may not apply to everyone. Semaglutide can cause side effects like nausea, vomiting, and diarrhea.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATRIAL FIBRILLATION (AF) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atrial fibrillation Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATRIAL FIBRILLATION (AF) OBESITY & OVERWEIGHT

Contacts and locations

Locations

Karolinska University Hospital
RECRUITING

Stockholm, 141 86, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.